secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001104659-25-019446
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma reports positive H5N1 ferret model data for tivoxavir marboxil
---------------------------------------------------------------------------

- Single oral dose of tivoxavir marboxil increased survival and reduced viral burden in lungs and nasal tissues in ferrets.
- Data consistent with December 2024 murine model results; non-human primate study expected Q1 2025.
- Company plans to approach FDA for accelerated approval under the Animal Rule after primate data.
- Virtual investor update on bird flu program scheduled for March 31, 2025.
- CEO Werner Cautreels and former CDC director Robert Redfield comment on urgency of bird flu threat.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925019446/0001104659-25-019446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925019446/tm258064d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-019446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer